Paradoxical oncogenesis: are all BRAF inhibitors equal?-Reference-Cited by-同舟云学术

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Published:2013-07-19 Issue:5 Volume:26 Page:611-615
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Menzies Alexander M.,Kefford Richard F.,Long Georgina V.

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12132/fullpdf

Reference40 articles.

1. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region;Amanuel;Pathology (Phila),2012

2. Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212);Andrews;Pigment Cell Melanoma Res.,2012

3. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib;Anforth;J. Clin. Oncol.,2012a

4. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors;Anforth;Pigment Cell Melanoma Res.,2012b

5. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma;Anforth;Br. J. Dermatol.,2012c

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma;Science Translational Medicine;2023-10-11

2. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment;Journal of Pediatric Hematology/Oncology;2023-09-13

3. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma;Biomedicines;2023-01-29

4. Recent advances in B-RAF inhibitors as anticancer agents;Bioorganic Chemistry;2022-03

5. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction;Journal of Experimental & Clinical Cancer Research;2022-02-07